FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 353:624-625 August 11, 2005 Number 6 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Black, D. M. Related Article by Cosman, F. PubMed Citation

For an investment approaching $1 billion, a pharmaceutical manufacturer may obtain approval from regulatory agencies to market a specific dose of a given medication for the treatment or prevention of a particular disorder. Such approval emphasizes and is based largely on the demonstration of simple efficacy and safety. Often little is known, not just about unanticipated side effects of the drug, much in the news of late, but also about such fundamental and critically important issues as the optimal duration of treatment; the effects, if any, of interactions with other agents affecting the same organs or tissues; or optimal sequencing . . . [Full Text of this Article]

Source Information

From the Osteoporosis Research Center, Creighton University, Omaha, Nebr.

This article has been cited by other articles:

• Whyte, M. P. (2006). The long and the short of bone therapy.. NEJM 354: 860-863 [Full Text]